COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Public ClinicalTrials.gov record NCT04354246. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Study identification
- NCT ID
- NCT04354246
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
- Dose escalation: COM902 monotherapy. Drug
- Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE) Combination Product
- Cohort expansion: COM902 (RDFE) monotherapy. Drug
- Cohort expansion: COM902 in combination with COM701 (both at the RDFE). Drug
- Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab. Combination Product
Drug · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2020
- Primary completion
- Mar 31, 2026
- Completion
- Mar 31, 2026
- Last update posted
- Aug 11, 2026
2020 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists | Sarasota | Florida | 34230 | — |
| Massachusetts General Hospital. | Boston | Massachusetts | 02114 | — |
| START Midwest. | Grand Rapids | Michigan | 49503 | — |
| The Ohio State University Comprehensive Cancer Center. | Columbus | Ohio | 43210 | — |
| The University of Tennessee WEST Cancer Center. | Memphis | Tennessee | 38138 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| MD Anderson Cancer Center. | Houston | Texas | 77030 | — |
| The START Center for Cancer Care. | San Antonio | Texas | 78229 | — |
| Froedtert & Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04354246, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 11, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04354246 live on ClinicalTrials.gov.